Skip to main content
. 2022 Oct 16;23(20):12387. doi: 10.3390/ijms232012387

Table 2.

Current targeted drugs for VTN and its receptors

Name Function Efficacy Company
SF0166 αvβ3 integrin inhibitor effect Scifulor
Flotegatide RGD peptide effect Siemens Medical Solutions
Thr-687 integrin antagonist ongoing Oxurion
Battifiban platelet GPIIb/IIIa receptor antagonist effect DongRui (Hangzhou) Medical Technology
Abciximab platelet GPIIb/IIIa receptor antagonist effect Janssen Biologics BV
Tirofiban platelet GPIIb/IIIa receptor antagonist effect Medicure Pharma